COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
StockStory
Collegium Pharmaceutical missed Q2 revenue expectations due to pricing pressure on its NUCYNTA pain franchise, despite reporting strong double-digit growth in its ADHD business driven by the successful integration of Azstarys. Consequently, the company lowered its full-year revenue guidance but maintained an upbeat outlook centered on expanding its CNS portfolio through strategic acquisitions and targeted commercial investments.
All articles from 10 August 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.